OTLK Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Outlook Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.00 |
52 Week High | US$40.60 |
52 Week Low | US$4.00 |
Beta | 0.28 |
1 Month Change | -1.11% |
3 Month Change | -6.78% |
1 Year Change | -73.15% |
3 Year Change | -84.38% |
5 Year Change | -84.31% |
Change since IPO | -98.83% |
Recent News & Updates
Recent updates
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?
Nov 03Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%
Aug 30Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01
Aug 10Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
Jul 06Outlook Therapeutics announces full cash pre-payment of convertible promissory note
Jul 05Outlook Therapeutics: A One-Buck Lottery Ticket
Jun 09Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?
Apr 01Outlook Therapeutics: Likely FDA Approval, Possible Buyout
Jan 21Outlook Therapeutics (NASDAQ:OTLK) Has Debt But No Earnings; Should You Worry?
Jun 24Shareholder Returns
OTLK | US Biotechs | US Market | |
---|---|---|---|
7D | 7.7% | 0.07% | -0.2% |
1Y | -73.2% | 6.9% | 28.2% |
Return vs Industry: OTLK underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: OTLK underperformed the US Market which returned 27.7% over the past year.
Price Volatility
OTLK volatility | |
---|---|
OTLK Average Weekly Movement | 18.7% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OTLK's share price has been volatile over the past 3 months.
Volatility Over Time: OTLK's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 24 | Russ Trenary | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.
Outlook Therapeutics, Inc. Fundamentals Summary
OTLK fundamental statistics | |
---|---|
Market cap | US$184.20m |
Earnings (TTM) | -US$159.13m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs OTLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OTLK income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$26.45m |
Gross Profit | -US$26.45m |
Other Expenses | US$132.68m |
Earnings | -US$159.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -6.80 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -33.3% |
How did OTLK perform over the long term?
See historical performance and comparison